Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).

Journal: Acta Dermato-Venereologica
Treatment Used: Aprepitant vs. Placebo
Number of Patients: 58
MediFind Summary

Overview: This study determined the effectiveness of aprepitant (antiemetic) versus placebo in patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo (skin disease with itchy nodules on the arms or legs).

Conclusion: This study concluded that aprepitant was not effective to treat patients with chronic nodular prurigo.


The aim of this multicentre, randomized, double-blind, placebo-controlled, cross-over, phase-II study was to determine the antipruritic effect of aprepitant vs. placebo in 58 patients with anti-histamine-refractory chronic pruritus in chronic nodular prurigo. Patients were randomized to receive either first oral aprepitant 80 mg/day or placebo for 4 weeks. Following a 2-week wash-out phase, the patients were crossed-over to receive the other treatment for 4 weeks. Primary efficacy criterion was the intra-individual difference between mean itch intensity (visual analogue scale) at baseline compared with the end of treatment period. Prurigo lesions, pruritus course, quality of life, patient benefits, and safety were secondary parameters. No significant differences were found between aprepitant treatment and placebo for any of the parameters investigated. Under the experimental conditions of the study, aprepitant, 80 mg daily for 4 weeks, did not have an antipruritic effect in patients with chronic prurigo. (DRKS00005594; EudraCT Number: 2013-001601-85).

Relevant Conditions

Prurigo Nodularis

Similar Latest Advances